Advanced Search

Journal of Traditional Chinese Medicine >

2022 , Vol. 42 >Issue 5: 687 - 692

DOI: https://doi.org/10.19852/j.cnki.jtcm.20220426.001

Research Articles

Sanguinarine suppresses cell proliferation, migration and invasion in nasopharyngeal carcinoma via inhibiting mTOR signaling

  • Mengzhe YANG ,
  • Beibei ZHANG ,
  • Zhenqiang LIANG ,
  • Nannan CHENG ,
  • Anqiao Lü ,
  • Jianyu YANG ,
  • Xingzhe GUO ,
  • Xianyu BAI ,
  • Yuanjiao HUANG ,
  • Aijun JIAO ,
  • Ning XU
Expand
  • 1 School of Basic Medical Sciences, Guangxi Medical University, Nanning 530021, China
    2 Institute of Biomedical Research, Yunnan University, Kunming 650500, China
    3 Department of Otolaryngology-Head and Neck Surgery, the Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, China
    4 Life Science Institute, Guangxi Medical University, Nanning 530021, China
    5 Pharmaceutical College, Guangxi Medical University, Nanning 530021, China
    6 Department of Neurology, the Fifth Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
XU Ning, Department of Neurology, The Fifth Affiliated Hospital of Guangxi Medical University, Nanning 530021, China, m189770838191@163.com; Telephone: +86-771-5358128
JIAO Aijun, Pharmaceutical College, Guangxi Medical University, Nanning 530021, China, 807249683@qq.com;

Received date: 2021-06-27

  Accepted date: 2021-09-22

  Online published: 2022-04-26

Supported by

Department of Science and Technology of Guangxi Zhuang Autonomous Region, China, Screening, Product Development and Mechanism Research of Anti-Nasopharyngeal Cancer Chinese Medicine Monomers(AB19110052);Natural Science Foundation of Guangxi, China, Epstein-Barr Virus Infection and Up-Regulation Mechanism of Invasion and Migration-Related Proteins S100A8 and S100A9 in Nasopharyngeal Carcinoma Cells(2015GXNSFAA139215);National Natural Science Foundation of China, Quantification, Validation, Functional Analysis and Construction of Regulatory Pathway of iTRAQ Serum Protein Molecular Markers in Nasopharyngeal Carcinoma(81260405)

Fold

Abstract

OBJECTIVE: To confirm the anti-NPC effect of sanguinarine (SA) through a series of wet experiments.

METHODS: NPC cell viability was determined by proliferation experiment. Cell clone formation experiment, cell scratch test, transwell migration and invasion experiment and flow cytometry-based cell apoptosis assay were further performed. In addition, Western blotting was performed to investigate the cell signaling pathway. All the relevant experimental data were statistically processed using SPSS 16.0 software.

RESULTS: The results showed that sanguinarine represented a time and dose dependent inhibition effects on NPC cell proliferation including the low differentiated CNE2 cells and high metastatic 5-8F cells, along with the cell cloning ability reduction. In addition, sanguinarine has a certain inhibitory effect on the invasion and migration of NPC cells. Mechanistically, sanguinarine displayed the anti-NPC effects mainly involved into the suppression of mTOR signaling and cell apoptosis, which is closely associated with the tumor growth and metastatic malignancy.

CONCLUSIONS: Collectively, we discover that sanguinarine is a new high-efficiency anti-NPC monomer of Chinese medicine, with a value for the follow-up pre-clinical research.

Key words： nasopharyngeal carcinoma; sanguinarine; TOR serine-threonine kinases; apoptosis

Cite this article

Mengzhe YANG , Beibei ZHANG , Zhenqiang LIANG , Nannan CHENG , Anqiao Lü , Jianyu YANG , Xingzhe GUO , Xianyu BAI , Yuanjiao HUANG , Aijun JIAO , Ning XU . Sanguinarine suppresses cell proliferation, migration and invasion in nasopharyngeal carcinoma via inhibiting mTOR signaling[J]. Journal of Traditional Chinese Medicine, 2022 , 42(5) : 687 -692 . DOI: 10.19852/j.cnki.jtcm.20220426.001

References

1. Brennan B. Nasopharyngeal carcinoma. Orphanet J Rare Dis 2006; 1: 23.
2. Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer 2011; 30: 114-9.
3. Lee HM, Okuda KS, González FE, et al. Current perspectives on nasopharyngeal carcinoma. Adv Exp Med Biol 2019; 1164: 11-34.
4. Peng L, Liu JQ; Chen YP, et al. The next decade of clinical trials in locoregionally advanced nasopharyngeal carcinoma. Br J Radiol 2019; 92: 20181031.
5. Saini VK, Sewal RK, Ahmad Y, et al. Prospective observational study of adverse drug reactions of anticancer drugs used in cancer treatment in a Tertiary Care Hospital. Indian J Pharm Sci 2015; 77: 687-93.
6. Orlikova B, Legrand N, Panning J, et al. Anti-inflammatory and anticancer drugs from nature. Cancer Treat Res 2014; 159: 123-43.
7. Mackraj I, Govender T, Gathiram P. Sanguinarine. Cardiovasc Ther 2008; 26: 75-83.
8. Zhang R, Wang G, Zhang PF, et al. Sanguinarine inhibits growth and invasion of gastric cancer cells via regulation of the DUSP4/ERK pathway. J Cell Mol Med 2017; 21: 1117-27.
9. Singh CK; Kaur S; George J, et al. Molecular signatures of sang-uinarine in human pancreatic cancer cells: a large scale label-free comparative proteomics approach. Oncotarget 2015; 6: 10335-48.
10. Kalogris C, Garulli C, Pietrella L, et al. Sanguinarine suppresses basal-like breast cancer growth through dihydrofolate reductase inhibition. Biochem Pharmacol 2014; 90: 226-34.
11. Mao YP, Tang LL, Chen L, et al. Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy. Chin J Cancer 2016; 35: 103.
12. Tian YM, Huang WZ, Yuan X, et al. The challenge in treating locally recurrent T3-4 nasopharyngeal carcinoma: the survival benefit and severe late toxicities of re-irradiation with intensity-modulated radiotherapy. Oncotarget 2017; 8: 43450-7.
13. Gangemi R, Paleari L, Orengo AM, et al. Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. Curr Med Chem 2009; 16: 1688-703.
14. Sinnung S, Janvilisri T, Kiatwuthinon P. Reversal of cisplatin sensitization and abrogation of cisplatin-enriched cancer stem cells in 5-8F nasopharyngeal carcinoma cell line through a suppression of Wnt/beta-catenin-signaling pathway. Mol Cell Biochem 2021; 476: 1663-72.
15. Lee AW, Ma BB, Ng WT, et al. Management of nasopharyngeal carcinoma: current practice and future perspective. J Clin Oncol 2015; 33: 3356-64.
16. Lee TK, Park C, Jeong SJ, et al. Sanguinarine induces apoptosis of human oral squamous cell carcinoma KB cells via inactivation of the PI3K/Akt signaling pathway. Drug Dev Res 2016; 77: 227-40.
17. Galadari S, Rahman A, Pallichankandy S, et al. Molecular targets and anticancer potential of sanguinarine-a benzophenanthridine alkaloid. Phytomedicine 2017; 34: 143-53.
18. Achkar IW, Mraiche F, Mohammad RM, et al. Anticancer potential of sanguinarine for various human malignancies. Future Med Chem 2017; 9: 933-50.
19. Wu GS. Role of mitogen-activated protein kinase phosphatases (MKPs) in cancer. Cancer Metastasis Rev 2007; 26: 579-85.
20. Vogt A, Tamewitz A, Skoko J, et al. The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1. J Biol Chem 2005; 280: 19078-86.
21. Burotto M, Chiou VL, Lee JM, et al. The MAPK pathway across different malignancies: a new perspective. Cancer 2014; 120: 3446-56.
22. Gaziano R, Moroni G, Buè C, et al. Antitumor effects of the benzophenanthridine alkaloid sanguinarine: Evidence and perspectives. World J Gastrointest Oncol 2016; 8: 30-9.
23. Ahmad N, Gupta S, Husain MM, et al. Differential antiproliferative and apoptotic response of sanguinarine for cancer cells versus normal cells. Clin Cancer Res 2000; 6: 1524-8.
24. Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-101.
25. Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell, 2017; 168: 960-76.
26. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991; 253: 905-9.
27. Jiang BH, Liu LZ. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat 2008; 11: 63-76.
28. Robb VA, Karbowniczek M, Klein-Szanto AJ, et al. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol 2007; 177: 346-52.
29. Siu MK, Tsai YC, Chang YS, et al. Transforming growth factor-β promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway. Oncogene 2015; 34: 4767-76.
30. Ghayad SE, Bieche I, Vendrell JA, et al. mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci 2008; 99: 1992-2003.
31. Ponziani F, Ojetti V, Tortora A, et al. The metabolic and toxico-logical considerations for mTOR inhibitors in the treatment of hepatocarcinoma. Expert Opin Drug Metab Toxicol 2011; 7: 1535-46.
32. Vivanco I; Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature rev Cancer 2002; 2: 489-501.
33. Zhong JT, Yu J, Wang HJ, et al. Effects of endoplasmic reticulum stress on the autophagy, apoptosis, and chemotherapy resistance of human breast cancer cells by regulating the PI3K/ AKT/mTOR signaling pathway. Tumour Biol 2017; 39: 1010428317697562.
34. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer cell 2007; 12: 9-22.
35. Hara K, Yonezawa K, Weng QP, et al. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem 1998; 273: 14484-94.
36. Pópulo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci 2012; 13: 1886-1918.
37. Eid SY, El-Readi MZ, Wink M. Synergism of three-drug combinations of sanguinarine and other plant secondary metabolites with digitonin and doxorubicin in multi-drug resistant cancer cells. Phytomedicine 2012; 19: 1288-97.
Options
Outlines

/

〈 〉